| 2025-12-19 |
详情>>
内部人交易：
Samuel George A. III股份增加1735.00股
|
| 2025-11-06 |
详情>>
股本变动：
变动后总股本23032.75万股
变动原因 ▼▲
- 原因：
- From June 30, 2025 to September 30, 2025
Shares issued through ATM financing
Shares issued upon exercise of stock options
Shares issued upon exercise of warrants
|
| 2025-11-06 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.28美元,归母净利润-6438.4万美元,同比去年增长-319.82%
|
| 2025-11-06 |
财报披露：
美东时间 2025-11-06 盘后发布财报
|
| 2025-08-12 |
详情>>
业绩披露：
2025年中报每股收益-0.15美元,归母净利润-3460.3万美元,同比去年增长-181.28%
|
| 2025-05-13 |
详情>>
业绩披露：
2025年一季报每股收益-0.02美元,归母净利润-413.9万美元,同比去年增长36.73%
|
| 2025-04-29 |
股东大会：
将于2025-06-26召开股东大会
会议内容 ▼▲
- 1.To elect seven directors to hold office until the 2026 annual meeting of shareholders and until their respective successors are duly elected and qualified. The nominees are Michael H. Mulroy, Dipti Amin, Deborah Andrews, Neal C. Bradsher, Brian M. Culley, Anula Jayasuriya, and Angus C. Russell.
2.To ratify the appointment of Moss Adams LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025.
3.To approve, on an advisory basis, the compensation paid to our named executive officers.
4.To approve an amendment to the Lineage Cell Therapeutics, Inc. 2021 Equity Incentive Plan to increase the number of common shares available thereunder by 19,500,000.
5.To transact such other business as may properly come before the Meeting or any adjournment or postponement thereof.
|
| 2025-04-29 |
股东大会：
将于2025-06-26召开股东大会
会议内容 ▼▲
- 1.To elect seven directors to hold office until the 2026 annual meeting of shareholders and until their respective successors are duly elected and qualified. The nominees are Michael H. Mulroy, Dipti Amin, Deborah Andrews, Neal C. Bradsher, Brian M. Culley, Anula Jayasuriya, and Angus C. Russell.
2.To ratify the appointment of Moss Adams LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025.
3.To approve, on an advisory basis, the compensation paid to our named executive officers.
4.To approve an amendment to the Lineage Cell Therapeutics, Inc. 2021 Equity Incentive Plan to increase the number of common shares available thereunder by 19,500,000.
5.To transact such other business as may properly come before the Meeting or any adjournment or postponement thereof.
|
| 2025-03-10 |
详情>>
业绩披露：
2024年年报每股收益-0.09美元,归母净利润-1860.9万美元,同比去年增长13.39%
|
| 2024-12-09 |
股东大会：
将于2025-01-27召开股东大会
会议内容 ▼▲
- 1.To approve, for purposes of complying with NYSE American LLC listing standards and requirements, the issuance of our common shares and common warrants pursuant to the terms of the securities purchase agreement, dated November 19, 2024, between us and Broadwood Partners, L.P., and our common shares issuable upon exercise of such common warrants.
2.To approve the adjournment of the Meeting, if necessary or advisable, to solicit additional proxies in favor of the foregoing proposal if there are not sufficient votes to approve such proposal at the time of the Meeting or any adjournment or postponement thereof.
|
| 2024-12-09 |
股东大会：
将于2025-01-27召开股东大会
会议内容 ▼▲
- 1.To approve, for purposes of complying with NYSE American LLC listing standards and requirements, the issuance of our common shares and common warrants pursuant to the terms of the securities purchase agreement, dated November 19, 2024, between us and Broadwood Partners, L.P., and our common shares issuable upon exercise of such common warrants.
2.To approve the adjournment of the Meeting, if necessary or advisable, to solicit additional proxies in favor of the foregoing proposal if there are not sufficient votes to approve such proposal at the time of the Meeting or any adjournment or postponement thereof.
|
| 2024-11-14 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.08美元,归母净利润-1533.6万美元,同比去年增长8.23%
|
| 2024-08-08 |
详情>>
业绩披露：
2024年中报每股收益-0.07美元,归母净利润-1230.2万美元,同比去年增长-28.13%
|
| 2024-05-09 |
详情>>
业绩披露：
2024年一季报每股收益-0.04美元,归母净利润-654.2万美元,同比去年增长-49.63%
|
| 2024-04-29 |
股东大会：
将于2024-06-11召开股东大会
会议内容 ▼▲
- 1.To elect eight directors to hold office until the 2025 annual meeting of shareholders and until their respective successors are duly elected and qualified.
2.To ratify the appointment of WithumSmith+Brown, PC as our independent registered public accounting firm for our fiscal year ending December 31, 2024.
3.To approve, on an advisory basis, the compensation paid to our named executive officers.
4.To transact such other business as may properly come before the Meeting or any adjournment or postponement thereof.
|
| 2024-04-29 |
股东大会：
将于2024-06-11召开股东大会
会议内容 ▼▲
- 1.To elect eight directors to hold office until the 2025 annual meeting of shareholders and until their respective successors are duly elected and qualified.
2.To ratify the appointment of WithumSmith+Brown, PC as our independent registered public accounting firm for our fiscal year ending December 31, 2024.
3.To approve, on an advisory basis, the compensation paid to our named executive officers.
4.To transact such other business as may properly come before the Meeting or any adjournment or postponement thereof.
|
| 2024-03-07 |
详情>>
业绩披露：
2023年年报每股收益-0.12美元,归母净利润-2148.6万美元,同比去年增长18.22%
|
| 2023-11-09 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.1美元,归母净利润-1671.1万美元,同比去年增长16.11%
|
| 2023-08-10 |
详情>>
业绩披露：
2023年中报每股收益-0.06美元,归母净利润-960.1万美元,同比去年增长30.68%
|
| 2023-07-27 |
股东大会：
将于2023-09-06召开股东大会
会议内容 ▼▲
- 1.To elect nine directors to hold office until the 2024 annual meeting of shareholders and until their respective successors are duly elected and qualified.
2.To ratify the appointment of WithumSmith+Brown, PC as our independent registered public accounting firm for our fiscal year ending December 31, 2023.
3.To approve, on an advisory basis, the compensation paid to our named executive officers.
4.To indicate, on an advisory basis, the preferred frequency of holding an advisory vote on the compensation of our named executive officers.
5.To approve an amendment to the Lineage Cell Therapeutics, Inc. 2021 Equity Incentive Plan to increase the number of common shares available thereunder by 19,500,000.
6.To approve an amendment to our articles of incorporation to increase the number of our authorized common shares from 250,000,000 to 450,000,000.
7.To approve the adjournment of the Meeting, if necessary or advisable, to solicit additional proxies in favor of Proposal 6 if there are not sufficient votes to approve Proposal 6.
8.To transact such other business as may properly come before the Meeting or any adjournment or postponement thereof.
|
| 2023-07-27 |
股东大会：
将于2023-09-06召开股东大会
会议内容 ▼▲
- 1.To elect nine directors to hold office until the 2024 annual meeting of shareholders and until their respective successors are duly elected and qualified.
2.To ratify the appointment of WithumSmith+Brown, PC as our independent registered public accounting firm for our fiscal year ending December 31, 2023.
3.To approve, on an advisory basis, the compensation paid to our named executive officers.
4.To indicate, on an advisory basis, the preferred frequency of holding an advisory vote on the compensation of our named executive officers.
5.To approve an amendment to the Lineage Cell Therapeutics, Inc. 2021 Equity Incentive Plan to increase the number of common shares available thereunder by 19,500,000.
6.To approve an amendment to our articles of incorporation to increase the number of our authorized common shares from 250,000,000 to 450,000,000.
7.To approve the adjournment of the Meeting, if necessary or advisable, to solicit additional proxies in favor of Proposal 6 if there are not sufficient votes to approve Proposal 6.
8.To transact such other business as may properly come before the Meeting or any adjournment or postponement thereof.
|
| 2022-04-29 |
股东大会：
将于2022-06-16召开股东大会
会议内容 ▼▲
- 1.To elect nine directors to hold office until the 2023 annual meeting of shareholders and until their respective successors are duly elected and qualified.
2.To ratify the appointment of WithumSmith+Brown, PC as our independent registered public accounting firm for our fiscal year ending December 31, 2022.
3.To approve, on an advisory basis, the compensation paid to our named executive officers.
4.To transact such other business as may properly come before the Meeting or any adjournment or postponement thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-08-03 |
股东大会：
将于2021-09-13召开股东大会
会议内容 ▼▲
- 1.To elect nine directors to hold office until the 2022 annual meeting of shareholders and until their respective successors are duly elected and qualified.
2.To ratify the appointment of WithumSmith+Brown, PC as our independent registered public accounting firm for our fiscal year ending December 31, 2021.
3.To approve, on an advisory basis, the compensation paid to our named executive officers.
4.To approve the Lineage Cell Therapeutics, Inc. 2021 Equity Incentive Plan.
5.To transact such other business as may properly come before the Meeting or any adjournment or postponement thereof.
|
| 2020-08-10 |
股东大会：
将于2020-09-22召开股东大会
会议内容 ▼▲
- 1.To elect seven directors to hold office until the 2021 annual meeting of shareholders and until their respective successors are duly elected and qualified.
2.To ratify the appointment of OUM & Co. LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2020.
3.To approve, on an advisory basis, the compensation paid to our named executive officers.
4.To transact such other business as may properly come before the Meeting or any adjournment or postponement thereof.
|
| 2019-06-14 |
股东大会：
将于2019-07-30召开股东大会
会议内容 ▼▲
- 1.To elect eight directors to hold office until the 2020 annual meeting of shareholders and until their respective successors are duly elected and qualified.
2.To ratify the appointment of OUM & Co. LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2019.
3.To approve, on an advisory basis, compensation paid to our named executive officers.
4.To amend our 2012 Equity Incentive Plan to increase the number of common shares authorized for issuance thereunder from 16,000,000 to 24,000,000.
5.To transact such other business as may properly come before the Meeting or any adjournment or postponement thereof.
|
| 2018-03-29 |
股东大会：
将于2018-05-01召开股东大会
会议内容 ▼▲
- 1. To elect nine (9) directors to hold office until the next Annual Meeting of Shareholders and until their respective successors are duly elected and qualified. The nominees of the Board of Directors are: Deborah Andrews, Neal C. Bradsher, Stephen C. Farrell, Alfred D. Kingsley, Aditya P. Mohanty, Michael H. Mulroy, Cavan Redmond, Angus C. Russell, and Michael D. West;
2. To ratify the appointment of OUM & Co. LLP as BioTime’s independent registered public accountants for the fiscal year ending December 31, 2018;
3. To approve an amendment to our Articles of Incorporation to increase the total number of authorized common shares, no par value, that we may issue from 150,000,000 shares to 250,000,000 shares;
4. To hold an advisory vote on executive compensation;
5. To transact such other business as may properly come before the meeting or any adjournments of the meeting.
|
| 2017-07-13 |
股东大会：
将于2017-08-09召开股东大会
会议内容 ▼▲
- 1. To elect nine (9) directors to hold office until the next Annual Meeting of Shareholders and until their respective successors are duly elected and qualified. The nominees of the Board of Directors are: Deborah Andrews, Neal C. Bradsher, Stephen C. Farrell, Alfred D. Kingsley, Aditya P. Mohanty, Michael H. Mulroy, Angus C. Russell, David Schlachet, and Michael D. West;
2. To ratify the appointment of OUM & Co. LLP as BioTime’s independent registered public accountants for the fiscal year ending December 31, 2017;
3. To approve an amendment to BioTime’s Equity Incentive that, if approved, will make an additional 6,000,000 common shares available for sale or the grant of stock options, restricted stock units, and other equity awards;
4. To hold an advisory vote on executive compensation;
5. To hold an advisory vote on the frequency of the advisory vote on executive compensation;
6. To approve an amendment to our Articles of Incorporation to increase the number of authorized common shares, no par value, that we may issue from 125,000,000 shares to 150,000,000 shares;
7. To transact such other business as may properly come before the meeting or any adjournments of the meeting.
|
| 2016-06-16 |
复牌提示：
2016-06-16 09:27:10 停牌，复牌日期 2016-06-16 09:53:59
|
| 2016-04-29 |
股东大会：
将于2016-06-09召开股东大会
会议内容 ▼▲
- 1. To elect nine (9) directors to hold office until the next Annual Meeting of Shareholders and until their respective successors are duly elected and qualified. The nominees of the Board of Directors are: Deborah Andrews, Neal C. Bradsher, Stephen C. Farrell, Alfred D. Kingsley, Aditya Mohanty, Michael H. Mulroy, Angus C. Russell, David Schlachet, and Michael D. West;
2. To ratify the appointment of OUM & Co. LLP as BioTime’s independent registered public accountants for the fiscal year ending December 31, 2016;
3. To approve an amendment to our Articles of Incorporation to increase the number of authorized common shares, no par value, that we may issue from 125,000,000 shares to 150,000,000 shares;
4. To transact such other business as may properly come before the meeting or any adjournments of the meeting.
|
| 2015-06-11 |
股东大会：
将于2015-07-10召开股东大会
会议内容 ▼▲
- 1.To elect ten (10) directors to hold office until the next Annual Meeting of Shareholders and until their respective successors are duly elected and qualified. The nominees of the Board of Directors are: Deborah Andrews, Neal C. Bradsher, Stephen L. Cartt, Stephen C. Farrell, Alfred D. Kingsley, Michael H. Mulroy, Angus C. Russell, David Schlachet, Judith Segall, and Michael D. West;
2.To ratify the appointment of OUM & Co. LLP as BioTime’s independent registered public accountants for the fiscal year ending December 31, 2015;
3.To approve certain amendments to the BioTime Equity Incentive Plan;
4.To hold an advisory vote on executive compensation;
5.To transact such other business as may properly come before the meeting or any adjournments of the meeting.
|